Medical application
Title
Date Published
Update on the use of erythropoiesis- stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma
September 2, 2009
Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention
August 19, 2009
The clinical impact of the physiological effects of erythropoietin and erythropoietin- stimulating agents on the incidence of malignancy, and hypertension: Beyond anaemia
August 1, 2009
Erythropoiesis-stimulating agents in patients with cancer: update on safety issues
July 29, 2009
Erythropoietin or Darbepoetin for patients with cancer–meta-analysis based on individual patient data
July 8, 2009
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
July 6, 2009
Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study
July 1, 2009
Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks
June 30, 2009
Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events
June 30, 2009
The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis
June 2, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
May 2, 2009
No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo.
May 1, 2009
Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
March 1, 2009
Current and upcoming erythropoiesis- stimulating agents, iron products, and other novel anemia medications.
March 1, 2009
Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss
February 24, 2009
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.
January 27, 2009
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin
January 19, 2009
Meta-analysis Confirms Concerns About Erythropoiesis-Stimulating Agents in Cancer Patients.
December 17, 2008
A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
December 1, 2008
Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
November 30, 2008